The estimated Net Worth of Gordon K Johnson is at least $232 Тысяча dollars as of 31 December 2019. Gordon Johnson owns over 20,000 units of Zevra Therapeutics Inc stock worth over $232,400 and over the last 10 years Gordon sold KMPH stock worth over $0.
Gordon has made over 5 trades of the Zevra Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Gordon bought 20,000 units of KMPH stock worth $7,800 on 31 December 2019.
The largest trade Gordon's ever made was buying 20,000 units of Zevra Therapeutics Inc stock on 31 December 2019 worth over $7,800. On average, Gordon trades about 3,077 units every 132 days since 2015. As of 31 December 2019 Gordon still owns at least 40,000 units of Zevra Therapeutics Inc stock.
You can see the complete history of Gordon Johnson stock trades at the bottom of the page.
Gordon's mailing address filed with the SEC is C/O KEMPHARM, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, FL, 34747.
Over the last 10 years, insiders at Zevra Therapeutics Inc have traded over $0 worth of Zevra Therapeutics Inc stock and bought 3,083,371 units worth $9,282,809 . The most active insiders traders include Street Capital Master Fund,..., David S Tierney и Travis C Mickle. On average, Zevra Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $246,727. The most recent stock trade was executed by R. La Duane Clifton on 13 January 2023, trading 635 units of KMPH stock currently worth $3,689.
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
Zevra Therapeutics Inc executives and other stock owners filed with the SEC include: